Category Archives: Cell Therapy

Laminine Testimonial - Stroke
Laminine is availabe in the Philippines!!! "The Closest Alternative To Stem Cell Therapy..." "The miracle formula from a 9-day-old fertilized hen eggs" For M...

By: Julfran Ytang

Link:
Laminine Testimonial - Stroke - Video

Poway, California (PRWEB) February 20, 2014

Four-and-a-half year old Dakota, a German Shepherd from Colorado, is managing the pain from osteoarthritis with the help of stem cell therapy thanks to Mountain Ridge Animal Hospital and Pain Management Center of Lafayette. Dakotas positive results showed almost immediately, and just a few months post stem cell therapy using Vet-Stem, Inc. services, he is doing activities that he has not done for years.

Dakota was diagnosed with hip dysplasia at just three years old, and in less than two years time his owners felt his quality of life had significantly started to deteriorate. Robert Landry, DVM at Mountain Ridge Animal Hospital and Pain Management Center has been doing regenerative cell therapy with Vet-Stem for six years, treating various types of orthopedic issues and arthritis in small animals, and determined Dakota was a good candidate for the procedure.

Dr. Landry began Dakotas procedure on a Tuesday in October by collecting a small sample of fat called the falciform fat pad, which was sent overnight to Vet-Stems lab in San Diego, California. Received the next morning, the lab processed Dakotas fat and created injectable doses of his own stem cells to be overnighted back to Dr. Landry. Thursday Dakota received his hip injections and recovery began.

Dakotas results were almost immediate, Dakotas owners expressed, He moves around with ease now and can even go up and down the stairs. Last week he jumped into the back of my SUV, which he hasn't done in years. Before the stem cell therapy Dakota never wagged his tail, and now he doesnt stop! His quality of life is so much better and he seems truly happier.

Dr. Landry and the team at Mountain Ridge Animal Hospital and Pain Management Center specialize in companion animal health care, striving to provide the highest quality in Veterinary health care and customer service. Some of their specialties are pain management, surgery, and regenerative medicine. By understanding and valuing the special role that pets play in a family Dr. Landry and team are genuine advocates for each pet's health and care.

About Vet-Stem, Inc. Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine. The company holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells. In the last decade over 10,000 animals have been treated using Vet-Stem, Inc.s services, and Vet-Stem is actively investigating stem cell therapy for immune-mediated and inflammatory disease, as well as organ disease and failure. For more on Vet-Stem, Inc. and Veterinary Regenerative Medicine, visit http://www.vet-stem.com or call 858-748-2004.

Read more from the original source:
Mountain Ridge Animal Hospital and Pain Management Center of Lafayette, Colorado Helps Local Shepherd Manage the Pain ...

Laminine Testimonial - Chronic Kidney Disease
Laminine is availabe in the Philippines!!! "The Closest Alternative To Stem Cell Therapy..." "The miracle formula from a 9-day-old fertilized hen eggs" For M...

By: Julfran Ytang

Visit link:
Laminine Testimonial - Chronic Kidney Disease - Video

Contact Information

Available for logged-in reporters only

Newswise WA, Seattle (February 17, 2014) A new study describes the complexity of the new T cell repertoire following immune-depleting therapy to treat multiple sclerosis, improving our understanding of immune tolerance and clinical outcomes.

In the Immune Tolerance Networks (ITN) HALT-MS study, 24 patients with relapsing, remitting multiple sclerosis received high-dose immunosuppression followed by a transplant of their own stem cells, called an autologous stem cell transplant, to potentially reprogram the immune system so that it stops attacking the brain and spinal cord. Data published today in the Journal of Clinical Investigation (http://www.jci.org/articles/view/71691?key=b64763243f594bab6646) quantified and characterized T cell populations following this aggressive regimen to understand how the reconstituting immune system is related to patient outcomes.

ITN investigators used a high-throughput, deep-sequencing technology (Adaptive Biotechnologies, ImmunoSEQTM Platform) to analyze the T cell receptor (TCR) sequences in CD4+ and CD8+ cells to compare the repertoire at baseline pre-transplant, two months post-transplant and 12 months post-transplant.

Using this approach, alongside conventional flow cytometry, the investigators found that CD4+ and CD8+ lymphocytes exhibit different reconstitution patterns following transplantation. The scientists observed that the dominant CD8+ T cell clones present at baseline were expanded at 12 months post-transplant, suggesting these clones were not effectively eradicated during treatment. In contrast, the dominant CD4+ T cell clones present at baseline were undetectable at 12 months, and the reconstituted CD4+ T cell repertoire was predominantly comprised of new clones.

The results also suggest the possibility that differences in repertoire diversity early in the reconstitution process might be associated with clinical outcomes. Nineteen patients who responded to treatment had a more diverse repertoire two months following transplant compared to four patients who did not respond. Despite the low number of non-responders, these comparisons approached statistical significance and point to the possibility that complexity in the T cell compartment may be important for establishing immune tolerance.

This is one of the first studies to quantitatively compare the baseline T cell repertoire with the reconstituted repertoire following autologous stem cell transplant, and provides a previously unseen in-depth analysis of how the immune system reconstitutes itself following immune-depleting therapy.

About The Immune Tolerance Network The Immune Tolerance Network (ITN) is a research consortium sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The ITN develops and conducts clinical and mechanistic studies of immune tolerance therapies designed to prevent disease-causing immune responses, without compromising the natural protective properties of the immune system. Visit http://www.immunetolerance.org for more information.

###

See original here:
Deep TCR Sequencing Reveals Extensive Renewal of the T Cell Repertoire Following Autologous Stem Cell Transplant in ...

Miami, FL (PRWEB) February 11, 2014

Global Stem Cells Group, Bioheart, Inc., and Paul Perito Urology announce plans to launch stem cell clinical trials for treatment of Erectile Dysfunction (ED).

Paul Perito, M.D. of Perito Urology in Coral Gables, Florida and the principal investigator of the trial study, titled, "An Open-label, Non-randomized, Single-center Study to Assess the Safety and Effects of Autologous Adipose-derived Stromal Cells Delivered into the Corpus Cavernosum in Patients with Erectile Dysfunction," aims to assess the safety and efficacy of stem cell implantation therapy in patients with ED.

The cell therapy in this study will be composed of stem cells derived from a patients own adipose (fat) tissue, harvested by syringe liposuction. The adipose stem cells will then be delivered into the corpus cavernosum of the penis.

Clinical trials will be held at Perito Urology, in cooperation with Global Stem Cells Group and Bioheart. Up to 20 patients will be enrolled.

Fort Myers Florida-based Emcyte Corporation, a leading provider of biotechnology products for platelet rich plasma and bone marrow concentrate grafting procedures, will be providing systems and kits to be used in the trial.

To learn more about Global Stem Cells Group's clinical trials, and for investor information, visit the Global Stem Cell Group website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.

About the Global Stem Cell Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

Original post:
Global Stem Cells, Inc., Bioheart, Inc., and Paul Perito Urology Announce Plans to Launch Stem Cell Clinical Trials ...

Webinar: Reimbursement Strategies for Stem Cell Therapy Products
Planning Your Payment Strategy in Early Product Development EXPERT SPEAKERS: Michael Werner, J.D., Executive Director, Alliance for Regenerative Medicine;...

By: Fernanda Torres

Link:
Webinar: Reimbursement Strategies for Stem Cell Therapy Products - Video